Jan 17 (Reuters) - Amgen Inc:
* OVERALL SURVIVAL ANALYSIS FROM KYPROLISÂ® (CARFILZOMIB) PHASE 3 ASPIRE TRIAL PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY Source text for Eikon: Further company coverage:
 